Key Takeaways
- • GNI Group to acquire 100% of Ayumi Pharmaceutical Holdings from Blackstone for approximately ¥44.8 billion, making Ayumi a wholly owned subsidiary of the Tokyo-listed pharmaceutical company.
- • Ayumi Pharmaceutical controls over 80% of Japan's domestic acetaminophen market through its flagship product Calonal and maintains strong positioning in rheumatology and orthopedic therapeutics with established sales infrastructure.
- • The acquisition significantly expands GNI Group's domestic pharmaceutical platform; pro-forma FY2026 group revenue is projected to reach approximately ¥65.2 billion compared to Ayumi's standalone FY2026 (ended March) revenue of ¥38.5 billion with operating profit of ¥3.5 billion.
- • Post-acquisition, GNI Group intends to leverage the combined entity's capabilities to accelerate domestic introduction of biosimilar products utilizing its overseas network and deploy self-developed products, positioning itself as a global biopharmaceutical company.
- • Blackstone Capital Partners Asia AYM Holding will become the largest shareholder in GNI Group following the issuance of 6,982,004 new shares, projected to hold 10.63% of GNI Group's voting rights post-transaction.
Summary
GNI Group announced on June 5, 2026, its plan to acquire Ayumi Pharmaceutical Holdings from U.S. investment fund Blackstone for approximately ¥44.8 billion in equity value. The transaction will result in Ayumi becoming a wholly owned subsidiary of GNI Group, consolidating one of Japan's leading specialty pharmaceutical companies under the Tokyo-listed group's ownership. This represents a strategic expansion of GNI Group's domestic pharmaceutical footprint and market positioning.
Ayumi Pharmaceutical represents a significant asset in Japan's pharmaceutical landscape, with its cornerstone product Calonal commanding over 80% of the domestic acetaminophen market. The company maintains robust market presence in the rheumatology and orthopedic fields, supported by an established commercial platform and product portfolio. For the fiscal year ended March 2026, Ayumi reported non-consolidated revenue of ¥38.5 billion and operating profit of ¥3.5 billion, demonstrating stable profitability in Japan's specialty pharmaceutical segment.
The acquisition is expected to materially strengthen GNI Group's operational scale and capabilities. Pro-forma combined group revenue for FY2026 is projected to expand to approximately ¥65.2 billion, reflecting the substantial contribution of Ayumi's sales and earnings base. Beyond financial consolidation, GNI Group intends to utilize the combined platform to accelerate the domestic introduction of biosimilar products by leveraging its overseas network and facilitate the deployment of self-developed therapeutic products, positioning the enlarged group as a competitive global biopharmaceutical company.
The transaction structure includes the issuance of 6,982,004 new GNI Group shares to BCP Asia AYM Holding, making Blackstone's investment vehicle the largest shareholder in GNI Group with projected voting rights of 10.63% post-completion. This shareholding arrangement aligns Blackstone's interests with GNI Group's long-term strategic execution while maintaining GNI's operational independence and Tokyo listing.
Ayumi Pharmaceutical represents a significant asset in Japan's pharmaceutical landscape, with its cornerstone product Calonal commanding over 80% of the domestic acetaminophen market. The company maintains robust market presence in the rheumatology and orthopedic fields, supported by an established commercial platform and product portfolio. For the fiscal year ended March 2026, Ayumi reported non-consolidated revenue of ¥38.5 billion and operating profit of ¥3.5 billion, demonstrating stable profitability in Japan's specialty pharmaceutical segment.
The acquisition is expected to materially strengthen GNI Group's operational scale and capabilities. Pro-forma combined group revenue for FY2026 is projected to expand to approximately ¥65.2 billion, reflecting the substantial contribution of Ayumi's sales and earnings base. Beyond financial consolidation, GNI Group intends to utilize the combined platform to accelerate the domestic introduction of biosimilar products by leveraging its overseas network and facilitate the deployment of self-developed therapeutic products, positioning the enlarged group as a competitive global biopharmaceutical company.
The transaction structure includes the issuance of 6,982,004 new GNI Group shares to BCP Asia AYM Holding, making Blackstone's investment vehicle the largest shareholder in GNI Group with projected voting rights of 10.63% post-completion. This shareholding arrangement aligns Blackstone's interests with GNI Group's long-term strategic execution while maintaining GNI's operational independence and Tokyo listing.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.